Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Modeling autosomal dominant Alzheimer's disease with machine learning
Luckett, Patrick H. , McCullough, Austin , Gordon, Brian A. , Strain, Jeremy F. , Flores, Shaney , Dincer, Aylin , Kuffner, Todd A. , Stern, Ari, Meeker, Karin L. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Oh, Hwamee , Swisher, Laura, Marcus, Daniel S. , Koudelis, Deborah, Joseph‐Mathurin, Nelly , Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Wang, Qing , Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Berman, Sarah , McCarthy, John Edward , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Wáng, Qīng , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 21, 2021 | Volume: 17 | Issue: 6 | Pages: 1005-1016

10.1002/alz.12259 | PMID 33480178 Get It

AbstractIntroductionMachine learning models were used to discover novel disease trajectories for autosomal dominant Alzheimer's disease.MethodsLongitudinal structural magnetic resonance imaging, amyloid positron emission tomography (PET), and fluorodeoxyglucose PET were acquired in 131 mutation carriers and 74 non‐carriers from the Dominantly Inherited Alzheimer Network; the groups were matched for age, education, sex, and apolipoprotein ε4 (APOE ε4). A deep neural network was trained to predict disease progression for each modality. Relief algorithms identified the strongest predictors of mutation status.ResultsThe Relief algorithm identified the caudate, cingulate, and precuneus as the strongest predictors among all modalities. The model yielded accurate results for predicting future Pittsburgh compound B (R2 = 0.95), fluorodeoxyglucose (R2 = 0.93), and atrophy (R2 = 0.95) in mutation carriers compared to non‐carriers.DiscussionResults suggest a sigmoidal trajectory for amyloid, a biphasic response for metabolism, and a gradual decrease in volume, with disease progression primarily in subcortical, middle frontal, and posterior parietal regions.
Differences in calculated percentage improvement versus patient-reported percentage improvement in pain scores: a review of spinal cord stimulation trials
Hagedorn, Jonathan M. , Deer, Timothy R. , Canzanello, Nicholas , Covington, Stephen , Schroeder, Darrell R. , Bendel, Markus A. , Moeschler, Susan M. , Hooten, W. Michael , Canzanello, Nicholas C, Covington, Stephen M, Hagedorn, Jonathan M , Deer, Tim , Schroeder, Darrell

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 21, 2021 | Volume: 46 | Issue: 4 | Pages: 293-297

10.1136/rapm-2020-102238 | PMID 33479116 Get It

Introduction Spinal cord stimulation is frequently used for the treatment of intractable chronic pain conditions. Trialing of the spinal cord stimulator device is recommended to assess the patient’s response to neurostimulation before permanent implantation. The trial response is often assessed by Numeric Rating Scale changes and patient-reported percentage pain improvement. Using number rating scale changes between prespinal and postspinal cord stimulation trial, a calculated percentage pain improvement can be obtained. The aim of this study was to assess the difference between calculated and patient-reported percentage improvement in pain scale during spinal cord stimulation trials. Methods This study was a retrospective single center review of all spinal cord stimulation trials from January 1 2017 to July 1 2019. A total of 174 patients were included. The paired t-test was used to compare numeric pain scores obtained prestimulation versus poststimulation. The mean difference between methods (patient-reported minus calculated) was compared with zero using the 1-sample t-test. Lin’s concordance correlation coefficient was computed with a 95% CI, calculated using Fisher z-transformation; and a bootstrapping approach was used to compare the concordance correlation coefficient between groups. In all cases, two-tailed tests were used with p<0.05 considered statistically significant. Results Based on prestimulation and poststimulation numeric rating scale scores, the mean±SD calculated percentage improvement in pain scale was 54±28. The mean±SD patient-reported percentage improvement in pain scale was 59±25. The overall 95% limits of agreement for the two methods are −30% to +41%. The overall concordance correlation coefficient was 0.76 (95% CI 0.69 to 0.81). Conclusion Although the two methods are highly correlated, there is substantial lack of agreement between patient-reported and calculated percentage improvement in pain scale, suggesting that these measures should not be used interchangeably for spinal cord stimulator trial outcome assessment. This emphasizes the need for improved metrics to better measure patient response to neuromodulation therapies. Additionally, patient-reported percentage improvement in pain was found to be higher than calculated percentage improvement in pain, potentially highlighting the multidimensional experience of pain and the unpredictability of solely using Numeric Rating Scale scores to assess patient outcomes.
The Effect of Patient Specific Factors on Occlusal Forces Generated: Best Evidence Consensus Statement
Lee, Sarah Kay Youny , Salinas, Thomas , Wiens, Jonathan P., Salinas, Thomas J

Mayo Clinic

Journal of Prosthodontics | January 21, 2021 | Volume: 30 | Issue: S1 | Pages: 52-60

10.1111/jopr.13334 | PMID 33474770 Get It

AbstractPurposeThe purpose of this Best Evidence Consensus Statement was to search the literature to determine if there is a relationship between patient specific factors and occlusal force.Materials and MethodsA literature review was conducted in the following databases: Evidence‐Based Medicine Reviews (EBMR), Cochrane Database of Systematic Reviews, Embase, and Ovid MEDLINE(R) and Epub Ahead of Print. Articles on patient factors and occlusal force were compiled by using a combination of the key words: “bite force,” “occlusal force,” “partial and complete edentulism,” “bruxism,” and “orthognathic class.” Inclusion criteria included meta‐analyses, systematic reviews, randomized controlled trials, case series, and journal articles. Exclusion criteria were case reports, studies in children, animals, and bench studies.ResultsOf the 1502 articles that met the initial search criteria, 97 related to patient‐specific factors affecting occlusal forces. These articles were evaluated, rated, and organized into appropriate categories addressing questions of foci.ConclusionsThe range of occlusal force is highly variable among subjects correlated to patient specific factors such as age, gender, partial and complete edentulism, the presence of a maxillofacial defect, location of edentulous area, orthognathic profile, and magnitude of occlusal vertical dimension. Tooth replacement therapies targeted at increasing occlusal contact seem to have a positive effect on increasing occlusal force. Bruxism does not necessarily demonstrate higher occlusal powering but may have greater tooth contact time. Occlusal force is not clearly affected by the type of dental restoration or restorative material used. The clinical significance of the changes in occlusal forces is yet to be determined.
Comparison of Functional and Radiographic Outcomes of Talar Osteochondral Lesions Repaired With Micronized Allogenic Cartilage Extracellular Matrix and Bone Marrow Aspirate Concentrate vs Microfracture
Drakos, Mark C. , Eble, Stephanie K. , Cabe, Taylor N., Patel, Karan A. , Hansen, Oliver B. , Sofka, Carolyn M., Deland, Jonathan T. , Patel, Karan , Fabricant, Peter D

Mayo Clinic

Foot & Ankle International | January 21, 2021 | Volume: 42 | Issue: 7 | Pages: 841-850

10.1177/1071100720983266 | PMID 33472436 Get It

Background: Microfracture (MF) has been used historically to treat osteochondral lesions of the talus (OLTs), with favorable outcomes reported in approximately 80% to 85% of cases. However, MF repairs have been shown to degrade over time at long-term follow-up, suggesting that further study into optimal OLT treatment is warranted. The use of adjuvant extracellular matrix with bone marrow aspirate concentrate (ECM-BMAC) has not been extensively evaluated in the literature. We present a comparison of patient-reported and radiographic outcomes following ECM-BMAC repair vs traditional MF. Methods: Patients who underwent MF (n = 67) or ECM-BMAC (n = 62) treatment for an OLT were identified and their charts were retrospectively reviewed. Postoperative magnetic resonance imaging (MRI) was evaluated and patient-reported outcome scores, either Foot and Ankle Outcome Scores (FAOS) or Patient-Reported Measurement Information System (PROMIS) scores, were collected. MRIs were scored by a radiologist, fellowship trained in musculoskeletal radiology, using the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) system. Radiographic and clinical outcomes were compared between groups. Results: On average, patients treated with ECM-BMAC demonstrated a higher total MOCART score compared to the MF group (73 ± SD 11.5 vs 54.0 ± 24.1; P = .0015). ECM-BMAC patients also had significantly better scores for the Infill, Integration, and Signal MOCART subcategories. Last, patients treated with ECM-BMAC had a lower rate of revision compared to those treated with MF (4.8% vs 20.9%; P = .007). FAOS scores were compared between groups, with no significant differences observed. Conclusion: When comparing outcomes between patients treated for an OLT with ECM-BMAC vs traditional MF, we observed superior MRI results for ECM-BMAC patients. The rate of revision surgery was higher for MF patients, although patient-reported outcomes were similar between groups. The use of ECM-BMAC as an adjuvant therapy in the treatment of OLTs may result in improved reparative tissue when compared to MF. Level of Evidence: Level III, comparative series.
Diagnostic Yield of Lateral Decubitus Digital Subtraction Myelogram Stratified by Brain MRI Findings
Kim, Dong Kun , Morris, Pearse , Verdoorn, Jared T. , Cutsforth‐Gregory, Jeremy K. , Atkinson, John L. D., Brinjikji, Waleed , Benson, John C. , Diehn, Felix E. , Lehman, Vance T. , Liebo, Greta B. , Morris, P Pearse, Cutsforth-Gregory, Jeremy K , Carr, Carrie M. , Morris, Jonathan M.

Mayo Clinic

Neurology | January 20, 2021 | Volume: 96 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000011522 | PMID 33472917 Get It

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study
Hutchings, Martin , Radford, John , Ansell, Stephen M. , Sureda, Anna , Connors, Joseph M. , Šýkorová, Alice , Shibayama, Hirohiko , Abramson, Jeremy S. , Chua, Neil , Friedberg, Jonathan W. , Kořen, Jan , LaCasce, Ann S. , Molina, Lysiane, Engley, Gerald, Fenton, Keenan , Jolin, Hina, Liu, Rachael , Gautam, Ashish , Gallamini, Andrea , Illés, Árpád , Connors, Joseph M , Sýkorová, Alice , Shibayama, Hirohiko , Abramson, Jeremy S , Chua, Neil S , Friedberg, Jonathan W , LaCasce, Ann Steward , Liu, Rachael , Gautam, Ashish , Gallamini, Andrea , Radford, John

Mayo Clinic

Hematological Oncology | January 18, 2021 | Volume: 39 | Issue: 2 | Pages: 185-195

10.1002/hon.2838 | PMID 33462822 Get It

Abstract Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high‐risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4–7, enrolled in the ECHELON‐1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first‐line therapy after a median follow‐up of 37.1 months. Among patients treated with A + AVD ( n = 664) or ABVD ( n = 670), 64% had Stage IV disease and 26% had an IPS of 4–7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537–0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4–7 (HR, 0.588; 95% CI, 0.386–0.894; p = 0.012). The most common adverse events (AEs) in A + AVD‐treated versus ABVD‐treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4–7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high‐risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON‐1 shows a favorable benefit‐risk balance in high‐risk patients.
Observation Versus Intervention for Low-Grade Intracranial Dural Arteriovenous Fistulas
Buell, Thomas J. , Ding, Dale , Guniganti, Ridhima , Kansagra, Akash P. , Brinjikji, Waleed , Kim, Louis J. , Levitt, Michael R. , Abecassis, Isaac Josh, Bulters, Diederik , Durnford, Andrew , Fox, W. Christopher , Polifka, Adam , Gross, Bradley A. , Hayakawa, M. , Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Alaraj, Ali , Kwasnicki, Amanda , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Starke, Robert M., Satomi, Junichiro, Tada, Yoshiteru , Abla, Adib A. , Lai, Rosalind, Zipfel, Gregory J. , Sheehan, Jason P. , Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J., Rao, Mohana Patibandla, Paisan, Gabriella, Meyer, R. Michael, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Millar, John S. , Macdonald, Jason, Laurent, Dimitri , Lockerman, Ashley, Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Samir, Sur, Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Winkler, Ethan A. , Lawton, Michael T. , Rutkowski, Martin J. , Sultan, M. Ali Aziz, Patel, Nirav J. , Frerichs, Kai U., Ding, Dale , Amin-Hanjani, Sepideh , Alaraj, Ali , Du, Rose , Levitt, Michael R , Fox, W Christopher , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching‐Jen , Lanzino, Giuseppe , Kim, Louis J. , Gross, Bradley , Samaniego, Edgar A , Chen, Stephanie , Phelps, Ryan , Raman, Hari S. , Lipsey, Kim L. , Giordan, Enrico , Link, Michael J. , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki

Mayo Clinic

Neurosurgery | January 14, 2021 | Volume: 88 | Issue: 6 | Pages: 1111-1120

10.1093/neuros/nyab024 | PMID 33582776 Get It

Abstract BACKGROUND Low-grade intracranial dural arteriovenous fistulas (dAVF) have a benign natural history in the majority of cases. The benefit from treatment of these lesions is controversial. OBJECTIVE To compare the outcomes of observation versus intervention for low-grade dAVFs. METHODS We retrospectively reviewed dAVF patients from institutions participating in the CONsortium for Dural arteriovenous fistula Outcomes Research (CONDOR). Patients with low-grade (Borden type I) dAVFs were included and categorized into intervention or observation cohorts. The intervention and observation cohorts were matched in a 1:1 ratio using propensity scores. Primary outcome was modified Rankin Scale (mRS) at final follow-up. Secondary outcomes were excellent (mRS 0-1) and good (mRS 0-2) outcomes, symptomatic improvement, mortality, and obliteration at final follow-up. RESULTS The intervention and observation cohorts comprised 230 and 125 patients, respectively. We found no differences in primary or secondary outcomes between the 2 unmatched cohorts at last follow-up (mean duration 36 mo), except obliteration rate was higher in the intervention cohort (78.5% vs 24.1%, P < .001). The matched intervention and observation cohorts each comprised 78 patients. We also found no differences in primary or secondary outcomes between the matched cohorts except obliteration was also more likely in the matched intervention cohort ( P < .001). Procedural complication rates in the unmatched and matched intervention cohorts were 15.4% and 19.2%, respectively. CONCLUSION Intervention for low-grade intracranial dAVFs achieves superior obliteration rates compared to conservative management, but it fails to improve neurological or functional outcomes. Our findings do not support the routine treatment of low-grade dAVFs.
Association Between Conflict of Interest and Published Position on Hypoglossal Nerve Stimulation for Sleep Apnea
Crossley, Jason R. , Wallerius, Katherine P. , Hoa, Michael , Davidson, Bruce J. , Giurintano, Jonathan P. , Wallerius, Katherine

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 13, 2021 | Volume: 165 | Issue: 2 | Pages: 375-380

10.1177/0194599820982914 | PMID 33400633 Get It

ObjectiveTo determine if there is an association between authors’ financial conflict of interest and published position on clinical use of hypoglossal nerve stimulation for obstructive sleep apnea.Study DesignRetrospective cross‐sectional analysis.SettingInternational roster of authors and articles analyzed.MethodsA Google Scholar search was performed for editorials and reviews citing the 2014 New England Journal of Medicine article on hypoglossal nerve stimulation for obstructive sleep apnea. Included articles were coded as favorable or neutral. Conflict of interest was recorded as declared by the authors in these articles and as independently searched in the Open Payments registry.ResultsSixteen articles from 45 independent authors were analyzed. Nine articles by authors were coded as favorable. Among authors of articles with favorable views, 16 (59%) had a financial conflict of interest with the manufacturer of the hypoglossal nerve stimulator device, as opposed to only 1 of 21 (5%) authors of neutral/unfavorable articles. When we included only authors to whom payments could be identified or excluded on Open Payments, 16 of 20 (80%; 95% CI, 62%‐98%) authors of favorable articles had a financial conflict, while 1 of 10 (10%; 95% CI, 0%‐29.6%) of neutral/unfavorable articles did (P =. 004).ConclusionOur study demonstrates an association between published position on hypoglossal nerve stimulator use and financial conflict with the device manufacturer. Several undeclared conflicts were also found, suggesting a role for independent search for conflicts during the review process.
Cognitive Impairment in Patients with Stroke
D’Souza, Caitlin E. , Greenway, Melanie R. F. , Graff‐Radford, Jonathan , Meschia, James F. , Meschia, James F

Mayo Clinic

Seminars in Neurology | January 8, 2021 | Volume: 41 | Issue: 01 | Pages: 075-084

10.1055/s-0040-1722217 | PMID 33418591 Get It

Abstract Despite substantial advances in stroke care, vascular cognitive impairment remains a prominent source of disability. Unlike sensorimotor impairments, cognition often continues to decline after stroke. An aging population will increase the prevalence of vascular cognitive impairment, with stroke playing an important role. Ten percent of patients presenting with stroke have pre-stroke dementia; an additional 10% will develop incident dementia with a first stroke, and 30% with a recurrent stroke. While stroke increases the risk of cognitive impairment, the presence of cognitive impairment also impacts acute stroke treatment and increases risk of poor outcome by nearly twofold. There is substantial overlap in the clinical and pathological aspects of vascular and degenerative dementias in many patients. How they relate to one another is controversial. The treatment of vascular cognitive impairment remains supportive, focusing on treating vascular risk factors. Cognitive rehabilitation after stroke is an area of active research, and existing pharmacologic treatments have limited benefit. Heightened awareness of cognitive impairment in the setting of stroke is imperative for prognostication and management, impetus for research and, ultimately, the discovery of efficacious treatments.